Skip to main content

Advertisement

Springer Nature Link
Log in

Use of Adjuvant Compositions Based on Squalene Ensures Induction of Neutralizing Antibodies against SARS-CoV-2

  • PHARMACOLOGY AND TOXICOLOGY
  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

Squalene-based adjuvant compositions that can provide effective induction of specific humoral immune response have been developed. Recombinant receptor-binding domain (RBD) of surface S-protein of SARS-CoV-2 was used to evaluate the properties of the composition. Immunization of mice with the developed squalene-based compositions in combination with RBD allows obtaining high titers of specific antibodies: from 105 to 2×106. The blood sera from immunized mice exhibit neutralizing activity against SARS-CoV-2 Delta variant (B.1.617.2) with a titer up to 1:2000.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Gregorio E, Caproni E, Ulmer JB. Vaccine adjuvants: mode of action. Front. Immunol. 2013;4:214. https://doi.org/10.3389/fimmu.2013.00214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Patent EA015817B1. Immunogenic composition comprising an oil in water emulsion adjuvant. Int. Cl. A61K 39/39, 30.12.2011.

  3. Patent EA027142B1. Improved method for preparing squalene. Int. Cl. C07C 11/21, 30.06.2017.

  4. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garçon N, Van Mechelen M. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011;29(13):2461-2473. https://doi.org/10.1016/j.vaccine.2011.01.011

    Article  CAS  PubMed  Google Scholar 

  5. Seubert A, Monaci E, Pizza M, O’Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 2008;180(8):5402-5412. https://doi.org/10.4049/jimmunol.180.8.5402

    Article  CAS  PubMed  Google Scholar 

  6. Cioncada R, Maddaluno M, Vo HTM, Woodruff M, Tavarini S, Sammicheli C, Tortoli M, Pezzicoli A, De Gregorio E, Carroll MC, D’Oro U, Piccioli D. Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells. PLoS One. 2017;12(10):e0185843. https://doi.org/10.1371/journal.pone.0185843

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Patent CN111388422A. Cationic squalene liposome and preparation method thereof (Translated). Int. Cl. A61K 47/18, 10.07.2020.

  8. Patent EP-0745388-B2. Mammalian vaccines composition comprising squalene or squalane, phospholipid and a surfactant as adjuvant. Priority: 1995/06/02.

  9. Facciolà A, Visalli G, Laganà A, Di Pietro A. An overview of vaccine adjuvants: current evidence and future perspectives. Vaccines (Basel). 2022;10(5):819. https://doi.org/10.3390/vaccines10050819

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zhang J, Hu Z, He J, Liao Y, Li Y, Pei R, Fang X, Zeng P, Fan R, Ou Z, Deng J, Zhou J, Guan W, Min Y, Deng F, Peng H, Zhang Z, Feng C, Xin B. Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. Emerg. Microbes Infect. 2021;10(1):1589-1597. https://doi.org/10.1080/22221751.2021.1951126

    Article  CAS  PubMed  Google Scholar 

  11. Starr TN, Czudnochowski N, Liu Z, Zatta F, Park YJ, Addetia A, Pinto D, Beltramello M, Hernandez P, Greaney AJ, Marzi R, Glass WG, Zhang I, Dingens AS, Bowen JE, Tortorici MA, Walls AC, Wojcechowskyj JA, De Marco A, Rosen LE, Zhou J, Montiel-Ruiz M, Kaiser H, Dillen JR, Tucker H, Bassi J, Silacci-Fregni C, Housley MP, di Iulio J, Lombardo G, Agostini M, Sprugasci N, Culap K, Jaconi S, Meury M, Dellota E Jr, Abdelnabi R, Foo SC, Cameroni E, Stumpf S, Croll TI, Nix JC, Havenar-Daughton C, Piccoli L, Benigni F, Neyts J, Telenti A, Lempp FA, Pizzuto MS, Chodera JD, Hebner CM, Virgin HW, Whelan SPJ, Veesler D, Corti D, Bloom JD, Snell G. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature. 2021;597:97-102. https://doi.org/10.1038/s41586-021-03807-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Coria LM, Saposnik LM, Pueblas Castro C, Castro EF, Bruno LA, Stone WB, Pérez PS, Darriba ML, Chemes LB, Alcain J, Mazzitelli I, Varese A, Salvatori M, Auguste AJ, Álvarez DE, Pasquevich KA, Cassataro J. A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations containing alum increases neutralizing antibodies, specific germinal center b cells and confers protection against SARS-CoV-2 infection in mice. Front. Immunol. 2022;13:844837. https://doi.org/10.3389/fimmu.2022.844837

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kleanthous H, Silverman JM, Makar KW, Yoon IK, Jackson N, Vaughn DW. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. NPJ Vaccines. 2021;6(1):128. https://doi.org/10.1038/s41541-021-00393-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA, Esina TI, Zaykovskaya AV, Pyankov OV, Borisevich SS, Shelemba AA, Chikaev AN, Ilyichev AA. Comparative immunogenicity of the recombinant receptor-binding domain of protein S SARS-CoV-2 obtained in prokaryotic and mammalian expression systems. Vaccines (Basel). 2022;10(1):96. https://doi.org/10.3390/vaccines10010096

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lodaya RN, Kanitkar AP, Ashraf A, Bamba D, Amiji MM, O’Hagan DT. A self-emulsified adjuvant system containing the immune potentiator alpha tocopherol induces higher neutralizing antibody responses than a squalene-only emulsion when evaluated with a recombinant Cytomegalovirus (CMV) pentamer antigen in mice. Pharmaceutics. 2023;15(1):238. https://doi.org/10.3390/pharmaceutics15010238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. State Research Center of Virology and Biotechnology “VECTOR”, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia

    E. A. Volosnikova, N. V. Volkova, V. V. Ermolaev, M. B. Borgoyakova, V. S. Nesmeyanova, A. V. Zaykovskaya, O. V. Pyankov, B. N. Zaitsev, S. V. Belenkaya, A. A. Isaeva & D. N. Shcherbakov

Authors
  1. E. A. Volosnikova
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. N. V. Volkova
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. V. V. Ermolaev
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. M. B. Borgoyakova
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. V. S. Nesmeyanova
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. A. V. Zaykovskaya
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. O. V. Pyankov
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. B. N. Zaitsev
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. S. V. Belenkaya
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. A. A. Isaeva
    View author publications

    You can also search for this author inPubMed Google Scholar

  11. D. N. Shcherbakov
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to E. A. Volosnikova.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 177, No. 2, pp. 188-192, February, 2024

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Volosnikova, E.A., Volkova, N.V., Ermolaev, V.V. et al. Use of Adjuvant Compositions Based on Squalene Ensures Induction of Neutralizing Antibodies against SARS-CoV-2. Bull Exp Biol Med 177, 221–224 (2024). https://doi.org/10.1007/s10517-024-06160-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-024-06160-6

Keywords